dc.contributor.author | Gillespie, SH | |
dc.contributor.author | Gosling, RD | |
dc.contributor.author | Uiso, LO | |
dc.contributor.author | Sam, NE | |
dc.contributor.author | Bongard, E | |
dc.contributor.author | Kanduma, Esther G | |
dc.contributor.author | Nyindo, M | |
dc.contributor.author | Morris, RW | |
dc.date.accessioned | 2013-05-27T12:44:07Z | |
dc.date.available | 2013-05-27T12:44:07Z | |
dc.date.issued | 2003 | |
dc.identifier.citation | Gillespie Sh, Gosling Rd, Uiso Lo, Sam Ne, Bongard E, Kanduma Eg, Nyindo M, Morris Rw (2003). The Bactericidal Activity Of Moxifloxacin In Patients With Pulmonary Tuberculosis. Am J Respir Crit Care Med. 168(11):1342-5., Gathoni, Ms. Kanduma Esther , Am J Respir Crit Care Med. 168(11):1342-5., (2003) | en |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/26253 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pubmed/12917230 | |
dc.description.abstract | Patients in Whom Acid-fast Bacilli Smear-positive Pulmonary Tuberculosis Was Newly Diagnosed Were Randomized To Receive 400 Mg Moxifloxacin, 300 Mg Isonaizid, Or 600 Mg Rifampin Daily For 5 Days. Sixteen-hour Overnight Sputa Collections Were Made For The 2 Days Before And For 5 Days Of Monotherapy. Bactericidal Activity Was Estimated By The Time Taken To Kill 50% Of Viable Bacilli (vt50) And The Fall In Sputum Viable Count During The First 2 Days Designated As The Early Bactericidal Activity (eba). The Mean Vt50 Of Moxifloxacin Was 0.88 Days (95% Confidence Interval [ci], 0.43-1.33 Days) And The Mean Eba Was 0.53 (95% Ci 0.28-0.79). For The Isoniazid Group, The Mean Vt50 Was 0.46 Days (95% Ci, 0.31-0.61 Days) And The Mean Eba Was 0.77 (95% Ci, 0.54-1.00). For Rifampin, The Mean Vt50 Was 0.71 Days (95% Ci, 0.48-0.95 Days) And The Mean Eba Was 0.28 (95% Ci, 0.15-0.41). Using The Eba Method, Isoniazid Was Significantly More Active Than Rifampin (p < 0.01) But Not Moxifloxacin. Using The Vt50 Method, Isoniazid Was More Active Than Both Rifampin And Moxifloxacin (p = 0.03). Moxifloxacin Has An Activity Similar To Rifampin In Human Subjects With Pulmonary Tuberculosis, Suggesting That It Should Undergo Further Assessment As Part Of A Short Course Regimen For The Treatment Of Drug-susceptible Tuberculosis. | en |
dc.description.uri | http://www.ncbi.nlm.nih.gov/pubmed/12917230 | |
dc.language.iso | en | en |
dc.publisher | University of Nairobi | en |
dc.title | Bactericidal Activitry Of Moxifloxacin In Patients With Pulmonary Tuberculosis | en |
dc.type | Article | en |
local.publisher | Deaprtment of Biochemistry | en |